In comparison, those with KRAS G12D/V mutated cancers (n = 7) progressed and died within 2 months.32 Nevertheless, selumetinib monotherapy had modest activity in refractory KRAS G12R mutated PDA, with median PFS and OS of 3 and 9 months, respectively.20 Several larger studies evaluating MEK inhibitors for unselected patients with advanced PDA showed no significant efficacy.33-36 Nevertheless, combination strategies with MEK or ERK inhibitors should be studied for pancreatic cancers with KRAS G12R mutations. Here, KRAS is linked to Patent ductus arteriosus.